| Fosamax (also Fosamax Plus D), generic alenronate sodium, is manufactured by Merck. It was approved by the Food and Drug Administration (FDA) in 1995 for the treatment of post-menopausal and steroid-induced osteoporosis and Paget’s disease. Osteoporosis is a condition that can lead to bone loss and increased risks of fractures. In Paget’s disease, bone grows back soft when it is repaired and can result in deformity.
The Fosamax claim is that it increases bone density. Fosamax has been a huge success for Merck, with sales of $2.5 billion in 2003 and $3.2 billion in 2005 (with 22 million prescriptions in the United States).
Fosamax is one of a group of drugs called bisphosphonates that are used in tablet form to treat osteoporosis and Paget’s disease, and intravenously to treat the effects of cancer in bone tissue. Recent studies have linked the use of bisphosphonates with Osteonecrosis of the Jaw(ONJ), which is also called Dead Jaw, Jaw Necrosis, and Bis-Phossy Jaw. See Fosamax Information and Warnings for more information about ONJ as a Fosamax side effect.
Suffered harm from Fosamax? You may have a lawsuit. Click here, for a top rated law firm to evaluate your legal rights.
Check out the following articles for more information about Fosamax, filing a Fosamax lawsuit and finding a Fosamax attorney.
Suffered harm from Fosamax? You may have a lawsuit. Click here, for a top rated law firm to evaluate your legal rights.
| 
State Law Center | Legal Links | Site Map | Privacy Policy | Media | About Us | Contact Us